

Note: This document has been translated from a part of the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail. The Company assumes no responsibility for this translation or for direct, indirect or any other forms of damages arising from the translation.

(Securities Code 4694)
June 8, 2021

To Shareholders with Voting Rights:

Kensuke Kondo
President and Representative Director
BML, Inc.
5-21-3 Sendagaya, Shibuya-ku, Tokyo

NOTICE OF THE 66TH ANNUAL GENERAL MEETING OF SHAREHOLDERS

We would like to express our appreciation for your continued support and patronage.

We are pleased to inform you that the 66th Annual General Meeting of Shareholders of BML, Inc. (the “Company”) will be held for the purposes as described below.

In order to prevent the spread of novel coronavirus disease (COVID-19), the Japanese government and prefectural governors are strongly recommending all persons to stay at home. In response to this situation, as a result of careful consideration, we will be holding the General Meeting of Shareholders upon conducting appropriate infection preventive measures.

In light of the situation with strong recommendation to stay at home, we would like to ask our shareholders to exercise voting rights in advance in writing or via the Internet, etc. to the extent possible, and strongly encourage you to refrain from attending the General Meeting of Shareholders, regardless of your physical condition, from the perspective of preventing the spread of COVID-19.

Please review the attached Reference Documents for the General Meeting of Shareholders, and exercise your voting rights by no later than 5:30 p.m. on Monday, June 28, 2021, Japan time.

1. Date and Time: Tuesday, June 29, 2021 at 10:00 a.m. Japan time

2. Place: Nishiki, South Tower 4F, Keio Plaza Hotel
2-2-1 Nishi-Shinjuku, Shinjuku-ku, Tokyo, Japan

In order to prevent the spread of COVID-19, we will make a space between seats at this General Meeting of Shareholders as well. Accordingly, the number of seats available to the shareholders will be substantially fewer than previous years. Therefore, you may be denied admission even if you visit the venue. Thank you very much for your understanding in advance.

3. Meeting Agenda:

- Matters to be reported:**
1. The Business Report, Consolidated Financial Statements for the Company’s 66th Fiscal Year (April 1, 2020 - March 31, 2021) and results of audits of the Consolidated Financial Statements by the Accounting Auditor and the Board of Corporate Auditors
 2. Non-consolidated Financial Statements for the Company’s 66th Fiscal Year (April 1, 2020 - March 31, 2021)

Proposals to be resolved:

- Proposal 1:** Distribution of Surplus
Proposal 2: Partial Amendments to the Articles of Incorporation
Proposal 3: Election of 9 Directors
Proposal 4: Election of 3 Corporate Auditors
Proposal 5: Election of 1 Substitute Corporate Auditor

- When attending the meeting, please submit the enclosed Voting Rights Exercise Form at the reception desk.
- You may exercise your voting rights by mail or electronic media (via the Internet, etc.). By following “Guidance

for Exercise of Voting Rights” on pages 3 and 4 of the Japanese version of this document, please exercise your voting rights by no later than 5:30 p.m. on Monday, June 28, 2021 Japan time.

- In the event that voting rights are exercised multiple times via the Internet, etc., only the final vote submitted shall be considered valid.
- In the event that voting rights are exercised in duplicate by mailing the Voting Rights Exercise Form and via the Internet, etc., the voting rights exercised through the Internet, etc. shall be considered valid.
- Any updates to the Reference Documents for the General Meeting of Shareholders, the Business Report, the Non-Consolidated Financial Statements, and the Consolidated Financial Statements will be posted on the Company’s website (<http://www.bml.co.jp>).

<Notes to shareholders>

- We may update the above measures depending upon the situation of the spread of the disease and announcements made by the government until the day of the General Meeting of Shareholders. Please check the Company’s website (<http://www.bml.co.jp>) on the Internet for the transmission of information.
- Exercising your voting rights by the Voting Rights Exercise Form entails infection risk during the course of sending back the Form and counting the votes. Therefore, if you are exercising your voting rights in advance, we would like to ask you to do so via the Internet to the extent possible.
- We will put in place alcohol disinfectants for shareholders near the reception desk at the venue.
(If you are attending the meeting, we would like to request you to bring and wear a face mask.)
- We will take your temperature near the venue. Shareholders who have a fever, seem to be in a poor physical condition, or came back to Japan from overseas within 14 days may be asked not to enter the venue and go home. Please notify the receptionist if you came back to Japan and 14 days have not yet passed.
- Operation staff of the General Meeting of Shareholders will take their temperatures, check their physical conditions, and wear face masks.
- From the viewpoint of shortening the duration of the meeting in order to prevent the spread of COVID-19, detailed explanation on matters to be reported (including audit reports) and on the proposals will be omitted. We would like to ask you to read through the Notice in advance.

Reference Documents for the General Meeting of Shareholders

Proposals and References

Proposal 1: Distribution of Surplus

The Company recognizes the appropriate return of profits to shareholders as one of its important management priorities and intends to strive for improvement of the dividend level commensurate with the consolidated financial results based on the basic policy of maintaining continuous, stable dividends.

The year-end dividend of surplus for this year shall be paid as follows, based on such basic policy.

Items Related to the Year-end Dividend

(1) Type of dividend property
Cash

(2) Items related to the allocation of dividend property and the total amount
50.0 yen per common share of the Company
Total amount: 2,032,353,200 yen

The annual dividend for this year will be 70.0 yen per share including the interim dividend of 20.0 yen per share which has been already paid.

(3) Date the distribution of surplus comes into effect
June 30, 2021

Proposal 2: Partial Amendments to the Articles of Incorporation

1. Reasons for the amendments

- (1) In response to the future business development, etc., the Company proposes to add a new business purpose to Article 2 of the current Articles of Incorporation.
- (2) To ensure that Directors and Corporate Auditors fully perform their expected roles, the Company proposes to establish new provisions in Article 27 and Article 35 of the current Articles of Incorporation. The provisions stipulate that the Company may partially exempt Directors' and Corporate Auditors' liability to the extent provided for under laws and regulations upon the Board of Directors' resolution. Each of the Corporate Auditors has previously given their approval to the amendment to Article 27.

2. Details of the amendments

The details of the amendments are as follows.

(Proposed amendments are underlined.)

Current	Proposed Amendments
<p>Article 2 (Purposes)</p> <p>The purposes of the Company shall be to engage in the following businesses:</p> <p>1. to 28. (Omitted)</p> <p>(Newly established)</p> <p><u>29.</u> research and development related to each of the foregoing items and any other incidental businesses.</p>	<p>Article 2 (Purposes)</p> <p>The purposes of the Company shall be to engage in the following businesses:</p> <p>1. to 28. (Unchanged)</p> <p><u>29. Personnel dispatching agency business; and</u></p> <p><u>30.</u> research and development related to each of the foregoing items and any other incidental businesses.</p>

Current	Proposed Amendments
<p data-bbox="229 219 756 286"><u>Article 27 (Limited Liability Agreement with Outside Directors)</u></p> <p data-bbox="285 295 794 595">The Company may conclude agreements with <u>Outside</u> Directors to limit their liability for damages due to neglect of their duties in accordance with Article 427, Paragraph 1 of the Companies Act. Provided, however, that the maximum amount of liability under the agreements shall be the amount stipulated by laws and regulations.</p>	<p data-bbox="829 219 1353 246"><u>Article 27 (Exemption of Directors' Liability)</u></p> <p data-bbox="890 255 1401 515"><u>Pursuant to Article 426, Paragraph 1 of the Companies Act, the Company may exempt Directors (including former Directors) from liability under Articles 423, Paragraph 1 of the said Act to the extent provided for under laws and regulations, upon the Board of Directors' resolution.</u></p> <p data-bbox="890 524 1401 860"><u>2. The Company may conclude agreements with Directors (excluding those who are Executive Directors, etc.) to limit their liability for damages due to neglect of their duties in accordance with Article 427, Paragraph 1 of the Companies Act. Provided, however, that the maximum amount of liability under the agreements shall be the amount stipulated by laws and regulations.</u></p>
<p data-bbox="229 878 756 945"><u>Article 35 (Limited Liability Agreement with Outside Corporate Auditors)</u></p> <p data-bbox="285 954 804 1249">The Company may conclude agreements with <u>Outside</u> Corporate Auditors to limit their liability for damages due to neglect of their duties in accordance with Article 427, Paragraph 1 of the Companies Act. Provided, however, that the maximum amount of liability under the agreements shall be the amount stipulated by laws and regulations.</p>	<p data-bbox="829 878 1353 945"><u>Article 35 (Exemption of Corporate Auditors' Liability)</u></p> <p data-bbox="890 954 1401 1249"><u>Pursuant to Article 426, Paragraph 1 of the Companies Act, the Company may exempt Corporate Auditors (including former Corporate Auditors) from liability under Articles 423, Paragraph 1 of the said Act to the extent provided for under laws and regulations, upon the Board of Directors' resolution.</u></p> <p data-bbox="890 1258 1401 1550"><u>2. The Company may conclude agreements with Corporate Auditors to limit their liability for damages due to neglect of their duties in accordance with Article 427, Paragraph 1 of the Companies Act. Provided, however, that the maximum amount of liability under the agreements shall be the amount stipulated by laws and regulations.</u></p>

Proposal 3: Election of 9 Directors

The terms of office of all 11 Directors will expire at the conclusion of this General Meeting of Shareholders. Accordingly, in order to expedite decision-making processes, the Company proposes to decrease the number of Directors by two and elect 9 Directors.

The candidates for Directors are as follows. Matters on the candidates for Directors are provided on pages 8 to 16.

No.	Name	Positions and responsibilities in the Company	Attendance at meetings of the Board of Directors
1	Kensuke Kondo (Reappointment)	President and Representative Director	100.0% 16 out of 16 times
2	Nobuki Arai (Reappointment)	Representative Director; Vice President; General Manager, Management Division; in charge of Credit Guarantee Department; Director, BML General Laboratory; General Manager, Overseas Business Office	100.0% 16 out of 16 times
3	Masato Chikira (Reappointment)	Director; Executive Officer; General Manager, System Division; General Manager, System Management Department	100.0% 16 out of 16 times
4	Norihisa Takebe (Reappointment)	Director; Operating Officer; General Manager, Planning Division; General Manager, Corporate Planning Department; General Manager, Sales Management Department; General Manager, Accounting Department	100.0% 16 out of 16 times
5	Yasushi Narabe (Reappointment)	Director; Operating Officer; General Manager, BML Clinical Testing Headquarters; General Manager, General Laboratory First Clinical Testing Department; General Manager, General Laboratory Second Clinical Testing Department; General Manager, General Laboratory Fourth Clinical Testing Department; General Manager, Reagent Department; General Manager, Operations Management Department	100.0% 16 out of 16 times

No.	Name	Positions and responsibilities in the Company	Attendance at meetings of the Board of Directors
6	Hideaki Osawa (Reappointment)	Director; Operating Officer; General Manager, Sales Management Division; General Manager, Sales Promotion Headquarters; General Manager, Solution Proposal Department; General Manager, Medical Research Business Division	100.0% 16 out of 16 times
7	Toshiyuki Kondo (Reappointment) (Outside) (Independent)	Director	100.0% 16 out of 16 times
8	Yukiko Yoritaka (Reappointment) (Outside) (Independent)	Director	100.0% 12 out of 12 times
9	Tatsuharu Arai (New appointment) (Outside) (Independent)		—

No.	Name (Date of birth)	Past experience, positions and responsibilities in the Company	Number of shares of the Company held
1	Kensuke Kondo (September 18, 1966) (Reappointment)	<p>May 1994 Obtained a medical license</p> <p>June 1994 Director of the Company</p> <p>June 2004 Operating Officer in charge of medical science</p> <p>June 2006 Director; Operating Officer in charge of medical science</p> <p>October 2011 Director; Operating Officer; General Manager, Advanced Technology & Development Division; Deputy General Manager, Sales Management Division</p> <p>April 2013 Director; Operating Officer; Deputy General Manager, Management Division</p> <p>January 2014 President and Representative Director</p> <p>To present</p> <p>[Significant concurrent positions]</p> <ul style="list-style-type: none"> • Chairman and Representative Director, Daiichi Kishimoto Clinical Laboratories, Inc. • Chairman and Representative Director, Okayama Medical Laboratory Company • Chairman and Representative Director, Kyodo Igaku Laboratories, Inc. • Chairman and Representative Director, PCL Japan, Inc. • Chairman and Representative Director, Japan Clinical Service, Inc. • Chairman and Representative Director, OPL, Inc. • President and Representative Director, BML Planning, Inc. • President and Representative Director, Estate Kogyo Limited Company <p>(Reasons for nomination)</p> <p>Dr. Kensuke Kondo has abundant experience and deep insight on overall medical industry from his experience as a doctor.</p> <p>Since assuming position as Representative Director in January 2014, he has been leading the Group's management. Based on his wealth of achievement from his excellent leadership, the Company has judged that he is personnel necessary to increase future corporate value of the Group, and therefore nominates him again as a candidate for Director.</p>	3,166,174

No.	Name (Date of birth)	Past experience, positions and responsibilities in the Company	Number of shares of the Company held
2	Nobuki Arai (March 30, 1960) (Reappointment)	<p>May 1989 Obtained a medical license</p> <p>May 1989 Worked for University of Toyama Hospital</p> <p>June 2005 Outside Corporate Auditor of the Company</p> <p>April 2007 Medical Director, Keiyu Hospital</p> <p>June 2009 Director of the Company</p> <p>December 2009 Director; Executive Officer; Director, BML General Laboratory</p> <p>July 2012 Director; Executive Officer; General Manager, General Laboratory Inspection Division; Director, BML General Laboratory</p> <p>April 2013 Director; Executive Officer; General Manager, General Laboratory Inspection Division; General Manager, Advanced Technology & Development Division; Director, BML General Laboratory</p> <p>January 2014 Director; Executive Officer; General Manager, Inspection Management Division; Director, BML General Laboratory</p> <p>June 2015 Director; Senior Executive Officer in charge of Sales Management Division; Director, BML General Laboratory</p> <p>February 2017 Director; Senior Executive Officer; General Manager, Planning Division; Director, BML General Laboratory</p> <p>June 2017 Representative Director; Senior Executive Officer; General Manager, Planning Division; in charge of Credit Guarantee Department; Director, BML General Laboratory</p> <p>June 2018 Representative Director; Senior Executive Officer; General Manager, Planning Division; in charge of Credit Guarantee Department; Director, BML General Laboratory; General Manager, Overseas Business Office</p> <p>April 2020 Representative Director; Senior Executive Officer; General Manager, Management Division; in charge of Credit Guarantee Department; Director, BML General Laboratory; General Manager, Overseas Business Office</p> <p>June 2020 Representative Director; Vice President; General Manager, Management Division; in charge of Credit Guarantee Department; Director, BML General Laboratory; General Manager, Overseas Business Office</p> <p>To present</p> <p>(Reasons for nomination) Dr. Nobuki Arai has abundant experience and deep insight on overall medical industry from his experience as a doctor. Since assuming position as a Director in June 2009, he has served in inspection, sales, planning and quality divisions, and after assuming position as Representative Director in June 2017, he has involved in the Company's overall business including overseas and management divisions. By utilizing such achievements, expertise as well as insights on management, the Company has judged that he is personnel necessary to increase future corporate value of the Group, and therefore nominates him again as a candidate for Director.</p>	68,183

No.	Name (Date of birth)	Past experience, positions and responsibilities in the Company	Number of shares of the Company held
3	Masato Chikira (May 25, 1955) (Reappointment)	<p>July 1979 Joined the Company</p> <p>February 1996 General Manager, System Department, System Division</p> <p>August 1998 Deputy General Manager, System Division</p> <p>June 2008 Operating Officer; Deputy General Manager, System Division</p> <p>June 2012 Director; Operating Officer; Deputy General Manager, System Division</p> <p>June 2014 Director; Executive Officer; General Manager, System Division; General Manager, Electronic Patient Chart System Department</p> <p>April 2021 Director; Executive Officer; General Manager, System Division; General Manager, System Management Department</p> <p>To present</p> <p>(Reasons for nomination) Since joining the Company, Mr. Masato Chikira has involved mainly in the systems division and has abundant experience and deep insight on the Company's overall business. By utilizing such achievements, expertise as well as insights on management, the Company has judged that he is personnel necessary to increase future corporate value of the Group, and therefore nominates him again as a candidate for Director.</p>	6,484

No.	Name (Date of birth)	Past experience, positions and responsibilities in the Company	Number of shares of the Company held
4	Norihisa Takebe (April 28, 1962) (Reappointment)	<p>April 1987 Joined The Kyowa Bank, Ltd. (currently Resona Bank, Limited)</p> <p>April 2013 General Manager, Yokohama Branch</p> <p>April 2015 Joined the Company; General Manager, Sales Management Department; General Manager, Accounting Department</p> <p>June 2015 General Manager, Related Business Department; General Manager, Sales Management Department; General Manager, Accounting Department</p> <p>October 2015 General Manager, Corporate Planning Department; General Manager, Related Business Department; General Manager, Sales Management Department; General Manager, Accounting Department</p> <p>April 2016 Operating Officer; General Manager, Corporate Planning Department; General Manager, Related Business Department; General Manager, Sales Management Department; General Manager, Accounting Department</p> <p>June 2016 Director; Operating Officer; Deputy General Manager, Planning Division; General Manager, Corporate Planning Department; General Manager, Related Business Department; General Manager, Sales Management Department; General Manager, Accounting Department</p> <p>April 2019 Director; Operating Officer; Deputy General Manager, Planning Division; General Manager, Corporate Planning Department; General Manager, Sales Management Department; General Manager, Accounting Department</p> <p>April 2020 Director; Operating Officer; General Manager, Planning Division; General Manager, Corporate Planning Department; General Manager, Sales Management Department; General Manager, Accounting Department</p> <p>To present</p> <p>(Reasons for nomination) Mr. Norihisa Takebe has knowledge and experience of financial business. Since joining the Company, he has involved mainly in accounting, corporate planning and group company management divisions and has abundant experience and deep insight on the Company's overall business. By utilizing such achievements, expertise as well as insights on management, the Company has judged that he is personnel necessary to increase future corporate value of the Group, and therefore nominates him again as a candidate for Director.</p>	3,090

No.	Name (Date of birth)	Past experience, positions and responsibilities in the Company	Number of shares of the Company held
5	Yasushi Narabe (July 20, 1959) (Reappointment)	<p>April 1982 Joined the Company</p> <p>April 2012 General Manager, Automatic Analysis Department</p> <p>April 2014 General Manager, General Laboratory Inspection Division; General Manager, Inspection Department II; General Manager, Microbial Inspection Department; General Manager, Operations Management Department</p> <p>June 2015 Operating Officer; General Manager, General Laboratory Inspection Division; General Manager, Inspection Planning Department; General Manager, Inspection Department I; General Manager, Inspection Department II; General Manager, Inspection Department IV; General Manager, Microbial Inspection Department; General Manager, Reagent Department; General Manager, Operations Management Department</p> <p>June 2018 Director; Operating Officer; General Manager, General Laboratory Inspection Division; General Manager, Inspection Department I; General Manager, Inspection Department II; General Manager, Inspection Department IV; General Manager, Reagent Department; General Manager, Operations Management Department</p> <p>January 2021 Director; Operating Officer; General Manager, BML Clinical Testing Headquarters; General Manager, General Laboratory First Clinical Testing Department; General Manager, General Laboratory Second Clinical Testing Department; General Manager, General Laboratory Fourth Clinical Testing Department; General Manager, Reagent Department; General Manager, Operations Management Department To present</p> <p>(Reasons for nomination) Since joining the Company, Mr. Yasushi Narabe has involved mainly in inspection division and has abundant experience and deep insight on the Company's overall business. By utilizing such achievements, expertise as well as insights on management, the Company has judged that he is personnel necessary to increase future corporate value of the Group, and therefore nominates him again as a candidate for Director.</p>	5,100

No.	Name (Date of birth)	Past experience, positions and responsibilities in the Company	Number of shares of the Company held
6	Hideaki Osawa (February 13, 1964) (Reappointment)	<p>September 1986 Joined the Company</p> <p>June 2001 General Manager, Sales Office I, Clinical Inspection Sales Department</p> <p>July 2008 General Manager, Kinki Sales Department</p> <p>June 2010 Representative Director, Japan Clinical Service, Inc.</p> <p>June 2015 Deputy General Manager, Sales Management Division</p> <p>April 2016 Operating Officer; Deputy General Manager, Sales Management Division; General Manager, Tokyo Branch</p> <p>July 2018 Operating Officer; Deputy General Manager, Sales Management Division; General Manager, Kanto Branch</p> <p>June 2019 Director; Operating Officer; Deputy General Manager, Sales Management Division; General Manager, Proposal Planning Department</p> <p>April 2020 Director; Operating Officer; General Manager, Sales Management Division; General Manager, Proposal Planning Department</p> <p>June 2020 Director; Operating Officer; General Manager, Sales Management Division; General Manager, Proposal Planning Department; General Manager, Preventative Medicine Marketing Department; General Manager, Medical Research Business Division</p> <p>April 2021 Director; Operating Officer; General Manager, Sales Management Division; General Manager, Sales Promotion Headquarters; General Manager, Solution Proposal Department; General Manager, Medical Research Business Division</p> <p>To present</p> <p>(Reasons for nomination) Since joining the Company, Mr. Hideaki Osawa has involved mainly in sales division and also served as Representative Director at a collection and delivery-related subsidiary, and he has abundant experience and deep insight on the Company's overall business. By utilizing such achievements, expertise as well as insights on management, the Company has judged that he is personnel necessary to increase the future corporate value of the Group, and therefore nominates him again as a candidate for Director.</p>	2,948

No.	Name (Date of birth)	Past experience, positions and responsibilities in the Company	Number of shares of the Company held
7	Toshiyuki Kondo (October 24, 1946) (Reappointment) (Outside) (Independent)	<p>July 1976 Obtained a medical license</p> <p>April 1980 Medical Economics Division, Health Insurance Bureau; Health Statistics Division, Statistics and Information Department</p> <p>September 1990 Joined SRL, Inc.</p> <p>July 1995 President and Representative Director</p> <p>April 2006 Director General, Chiba Prefectural Hospitals Bureau</p> <p>April 2011 Managing Director, Miyagi Prefectural Hospital Organization</p> <p>January 2013 Senior Managing Director, VHJ Organization (NPO)</p> <p>June 2019 Outside Director of the Company</p> <p>To present</p> <p>[Significant concurrent positions]</p> <p>• Managing Director, Miyagi Prefectural Hospital Organization</p> <p>(Reasons for nomination as a candidate for Outside Director and summary of expected roles)</p> <p>Dr. Toshiyuki Kondo has abundant experience and deep insights on overall medical industry from his experience as a doctor, as well as abundant experience and deep insights on corporate management. By utilizing such achievements, expertise as well as insights on management, the Company judged that he is personnel necessary to increase future corporate value of the Group through giving opinions and making judgements from an objective standpoint when making decisions for the management of the Company, and through playing a role of monitoring and supervising Directors' execution of duties, and therefore nominates him again as a candidate for Outside Director. The Company expects him to fulfill his role of supervising the management from a position independent from executive officers by utilizing his wealth of experience in the overall medical industry.</p> <p>It has been two years since the appointment of Dr. Toshiyuki Kondo as Outside Director of the Company as of the conclusion of this Annual General Meeting of Shareholders.</p>	0

No.	Name (Date of birth)	Past experience, positions and responsibilities in the Company	Number of shares of the Company held
8	Yukiko Yoritaka (July 9, 1964) (Reappointment) (Outside) (Independent)	<p>April 1987 Joined The Sumitomo Bank, Limited (currently Sumitomo Mitsui Banking Corporation)</p> <p>April 2016 Executive Officer; General Manager, Learning and Development Institute, Human Resources Department, Sumitomo Mitsui Banking Corporation; Representative Director and President, SMBC LEARNING SUPPORT CO., LTD.</p> <p>April 2017 Executive Officer; General Manager, Learning and Development Institute, Human Resources Department, Sumitomo Mitsui Banking Corporation; Representative Director and President, SMBC LEARNING SUPPORT CO., LTD.; Executive Officer; General Manager, Learning and Development Institute, Human Resources Department, Sumitomo Mitsui Financial Group, Inc.</p> <p>April 2020 Executive Officer; Deputy in charge of Human Resources Department, Sumitomo Mitsui Banking Corporation; Executive Officer; Deputy in charge of Human Resources Department, Sumitomo Mitsui Financial Group, Inc.</p> <p>June 2020 Outside Director of the Company</p> <p>May 2021 Managing Director, The Japan Research Institute, Limited; Executive Officer, Sumitomo Mitsui Financial Group, Inc.</p> <p>To present</p> <p>[Significant concurrent positions]</p> <ul style="list-style-type: none"> • Managing Director, The Japan Research Institute, Limited • Executive Officer, Sumitomo Mitsui Financial Group, Inc. <p>(Reasons for nomination as a candidate for Outside Director and summary of expected roles)</p> <p>Ms. Yukiko Yoritaka has abundant experience and deep insights on finance and human resources fields. By utilizing such achievements, expertise as well as insights on management, the Company judged that she is personnel necessary to increase future corporate value of the Group through giving opinions and making judgements from an objective standpoint when making decisions for the management of the Company, and through playing a role of monitoring and supervising Directors' execution of duties, and therefore nominates her again as a candidate for Outside Director. The Company expects her to fulfill her role of supervising the management from a position independent from executive officers by utilizing her wealth of experience in finance and human resources fields.</p> <p>It has been one year since the appointment of Ms. Yukiko Yoritaka as Outside Director of the Company as of the conclusion of this Annual General Meeting of Shareholders.</p>	69

No.	Name (Date of birth)	Past experience, positions and responsibilities in the Company	Number of shares of the Company held
9	Tatsuharu Arai (October 20, 1956) (New appointment) (Outside) (Independent)	<p>April 1982 Joined Showa Denko K.K.</p> <p>March 2004 General Manager, Production Technology Department, Kawasaki Plant</p> <p>March 2006 Head, Kawasaki Plant</p> <p>January 2008 General Manager, Electronic Chemicals Department, Chemicals Division, Head Office</p> <p>March 2010 General Manager, Production Technology Department, Head Office</p> <p>January 2012 Corporate Officer; Representative, Oita Complex, Oita Plant</p> <p>January 2014 Corporate Officer; General Manager, Petrochemicals Division, Head Office</p> <p>January 2017 Managing Corporate Officer; General Manager, Petrochemicals Division</p> <p>January 2018 President and Representative Director, UNION SHOWA K.K.</p> <p>January 2021 Corporate Advisor</p> <p>To present</p> <p>[Significant concurrent positions]</p> <p>• Corporate Advisor, UNION SHOWA K.K.</p> <p>(Reasons for nomination as a candidate for Outside Director and summary of expected roles)</p> <p>Mr. Tatsuharu Arai has many years of abundant experience and deep insights on corporate management in the chemical industry. By utilizing such achievements, expertise as well as insights on management, the Company judged that he is personnel necessary to increase future corporate value of the Group through giving opinions and making judgements from an objective standpoint when making decisions for the management of the Company, and through playing a role of monitoring and supervising Directors' execution of duties, and therefore nominates him as a candidate for Outside Director.</p> <p>The Company expects him to fulfill his role of supervising the management from a position independent from executive officers by utilizing his wealth of experience in the chemical industry.</p>	0

(Notes)

1. There are no special interests between the candidates for Directors and the Company.
2. Attendance at meetings of the Board of Directors by Ms. Yukiko Yoritaka aggregates the number of the meetings held after she assumed office as Director.
3. Dr. Toshiyuki Kondo, Ms. Yukiko Yoritaka, and Mr. Tatsuharu Arai are candidates for Outside Directors.
4. The Company has registered Dr. Toshiyuki Kondo and Ms. Yukiko Yoritaka as Independent Directors with the Tokyo Stock Exchange.
5. If Mr. Tatsuharu Arai is elected as proposed, the Company will register him as an Independent Director with the Tokyo Stock Exchange.
6. The Company has entered into an agreement with Dr. Toshiyuki Kondo and Ms. Yukiko Yoritaka in accordance with Article 427, Paragraph 1 of the Companies Act to limit their liability for damages under Article 423, Paragraph 1 of the same act. The maximum amount of liability for damages pursuant to the agreement is the minimum amount stipulated by laws and regulations. If they are reelected and assume office as Outside Directors of the Company, the agreement shall continue to be effective.
7. If Mr. Tatsuharu Arai is elected as proposed, the Company intends to enter into an agreement with him in accordance with Article 427, Paragraph 1 of the Companies Act to limit his liability for damages under Article 423, Paragraph 1 of the same act. The maximum amount of liability for damages pursuant to the agreement will be the minimum amount stipulated by laws and regulations.
8. The Company has concluded with an insurance company a directors and officers liability insurance contract as stipulated in Article 430-3, Paragraph 1 of the Companies Act. This contract covers damages that may arise due to the insured being liable for performance of duties or receiving a claim related to the pursuit of such liability. However, the contract includes certain exclusions, such as no coverage for liability resulting from actions taken with the knowledge that they violate laws and regulations. The Company bears 90% of the premium, including riders, and the insured is substantially responsible for paying 10%. The candidates will be insured under the said insurance contract, which is to be renewed on March 1, 2022 during their terms of office.
9. The number of shares of the Company held by each candidate for Director refers to the actual number of shares held by each of them including the shares under the BML Group officers' shareholding association.

Proposal 4: Election of 3 Corporate Auditors

The terms of office of all three Corporate Auditors will expire at the conclusion of this General Meeting of Shareholders. Accordingly, we propose the election of three Corporate Auditors.

The Board of Corporate Auditors has previously given its approval to this proposal.

The candidates for Corporate Auditors are as follows. Matters on the candidates for Corporate Auditors are provided on pages 17 to 18.

No.	Name (Date of birth)	Past experience and positions in the Company	Number of shares of the Company held
1	Kenichi Morishita (August 6, 1958) (Reappointment)	<p>March 1985 Joined the Company April 2008 Deputy General Manager, Personnel Department April 2014 General Manager, Related Business Department June 2015 Director; General Manager, Management Department, OPL, Inc. June 2017 Corporate Auditor of the Company To present</p> <p>[Significant concurrent positions] • Auditor, Kondou Kinen Medical Foundation</p> <p>(Reasons for nomination) Since joining the Company, Mr. Kenichi Morishita has served in personnel and group company management divisions of the Company, as well as management division of its subsidiary engaged in clinical testing business. He therefore has abundant experience and deep insight in the Company's overall business. By utilizing such experience and insight, the Company has judged that he can enhance the audit structure of the Company, and therefore nominates him as a candidate for Corporate Auditor.</p>	793
2	Nobushige Tokuono (March 9, 1954) (Reappointment) (Outside) (Independent)	<p>April 1976 Joined Tokyo Regional Taxation Bureau July 2012 Head, Tokyo Ueno Tax Office July 2013 General Manager, Examination Department IV, Tokyo Regional Taxation Bureau July 2014 Left Tokyo Regional Taxation Bureau August 2014 Registered as certified public tax accountant August 2014 Representative, Nobushige Tokuono Tax Accountant Office June 2017 Outside Corporate Auditor of the Company To present</p> <p>[Significant concurrent positions] • Representative, Nobushige Tokuono Tax Accountant Office • Outside Corporate Auditor, DYNAM Co., Ltd. • Outside Corporate Auditor, TOH-TEN-KOH Corporation • Outside Corporate Auditor, Systema Corporation</p> <p>(Reasons for nomination as a candidate for Outside Corporate Auditor) The Company has judged that Mr. Nobushige Tokuono can utilize his expertise as a certified public tax accountant and abundant experience gained at the Tokyo Regional Taxation Bureau to enhance the audit structure of the Company, and therefore nominates him as a candidate for Corporate Auditor. It has been four years since the appointment of Mr. Nobushige Tokuono as Outside Corporate Auditor of the Company as of the conclusion of this Annual General Meeting of Shareholders.</p>	1,486

No.	Name (Date of birth)	Past experience and positions in the Company	Number of shares of the Company held
3	Masato Denawa (February 5, 1964) (New appointment) (Outside) (Independent)	<p>April 1990 Registered as attorney at law (Dai-ichi Tokyo Bar Association) January 1999 Joined Okinobu Ishihara Law Office (currently, Spring Partners) Partner, Spring Partners (incumbent) To present</p> <p>[Significant concurrent positions]</p> <ul style="list-style-type: none"> • Supervising Officer, Japan Prime Realty Investment Corporation • Outside Auditor, Ichikawa Co., Ltd. • Accident compensation examination commission member, Supreme Court of Japan <p>(Reasons for nomination as a candidate for Outside Corporate Auditor) Although he has never been involved in corporate management, the Company has judged that Mr. Masato Denawa can utilize his expertise and abundant experience as an attorney at law to enhance the audit structure of the Company, and therefore nominates him as a candidate for Corporate Auditor.</p>	0

(Notes)

1. There are no special interests between the candidates for Corporate Auditors and the Company.
2. Mr. Nobushige Tokuono and Mr. Masato Denawa are candidates for Outside Corporate Auditors.
3. The Company has registered Mr. Nobushige Tokuono as an Independent Corporate Auditor with the Tokyo Stock Exchange.
4. If Mr. Masato Denawa is elected as proposed, the Company will register him as an Independent Corporate Auditor with the Tokyo Stock Exchange.
5. The Company has entered into an agreement with Mr. Nobushige Tokuono in accordance with Article 427, Paragraph 1 of the Companies Act to limit his liability for damages under Article 423, Paragraph 1 of the same act. The maximum amount of liability for damages pursuant to the agreement is the minimum amount stipulated by laws and regulations.
6. If Mr. Masato Denawa is elected as proposed, the Company intends to enter into an agreement with him in accordance with Article 427, Paragraph 1 of the Companies Act to limit his liability for damages under Article 423, Paragraph 1 of the same act. The maximum amount of liability for damages pursuant to the agreement will be the minimum amount stipulated by laws and regulations.
7. The Company has concluded with an insurance company a directors and officers liability insurance contract as stipulated in Article 430-3, Paragraph 1 of the Companies Act. This contract covers damages that may arise due to the insured being liable for performance of duties or receiving a claim related to the pursuit of such liability. However, the contract includes certain exclusions, such as no coverage for liability resulting from actions taken with the knowledge that they violate laws and regulations. The Company bears 90% of the premium, including riders, and the insured is substantially responsible for paying 10%. The candidates will be insured under the said insurance contract, which is to be renewed on March 1, 2022 during their terms of office.
8. The number of shares of the Company held by each candidate for Corporate Auditor refers to the actual number of shares held by each of them including the shares under the BML Group officers' shareholding association.

Proposal 5: Election of 1 Substitute Corporate Auditor

In order to prepare for cases where a vacancy results in a shortfall in the number of Corporate Auditors prescribed by laws and regulations, we propose the election of one Substitute Corporate Auditor.

The Board of Corporate Auditors has previously given its approval to this proposal.

The candidate for Substitute Corporate Auditor is as follows:

Name (Date of birth)	Past experience and significant concurrent positions		Number of shares of the Company held
Shunsuke Nohara (November 11, 1979) (Outside)	October 2006	Registered as attorney at law (Dai-ichi Tokyo Bar Association) Joined KOHWA SOHGOH LAW OFFICES	0
	August 2015	Joined Kelvin Chia Partnership	
	January 2016	Admitted as attorney at law in New York, USA	
	October 2016	Partner, KOHWA SOHGOH LAW OFFICES (incumbent) To present	
	(Reasons for nomination as a candidate for Substitute Outside Corporate Auditor) The Company proposes that Mr. Shunsuke Nohara be elected as Substitute Corporate Auditor since we judged that his expertise as an attorney at law and abundant experience as a corporate lawyer can be used for enhancing the audit structure of the Company, even though he has never been involved in corporate management.		

(Notes)

1. Mr. Shunsuke Nohara is a candidate for Substitute Outside Corporate Auditor.
2. The Company has not entered into an advisory contract with the candidate.
3. The Company has entered into agreements with Outside Corporate Auditors in accordance with Article 427, Paragraph 1 of the Companies Act to limit their liability for damages pursuant to Article 423, Paragraph 1 of the same act. The maximum amount of liability for damages pursuant to the agreements is the minimum amount stipulated by laws and regulations. If the candidate is elected and assumes office as Outside Corporate Auditor, the Company intends to conclude the same agreement with him.
4. The Company has concluded with an insurance company a directors and officers liability insurance contract as stipulated in Article 430-3, Paragraph 1 of the Companies Act. This contract covers damages that may arise due to the insured being liable for performance of duties or receiving a claim related to the pursuit of such liability. However, the contract includes certain exclusions, such as no coverage for liability resulting from actions taken with the knowledge that they violate laws and regulations. The Company bears 90% of the premium, including riders, and the insured is substantially responsible for paying 10%. If the candidate assumes office as Outside Corporate Auditor, he will be insured under the said insurance contract.
5. Mr. Shunsuke Nohara satisfies the requirement as Independent Corporate Auditor prescribed by the Tokyo Stock Exchange. If he assumes office as Outside Corporate Auditor, the Company will register him as an Independent Corporate Auditor with the Tokyo Stock Exchange.

(Reference) Composition of the Board (after this General Meeting of Shareholders)

Directors:

Name	Positions in the Company	Areas which the Company specifically expect candidates for Directors to cover							
		Management Experience	Medical Experience	Inspection/Engineering	Information Technology	Strategy Planning	Finance/Accounting	Personnel/Labor	Risk/Legal Affairs
Kensuke Kondo	President and Representative Director	○	○	○		○			○
Nobuki Arai	Representative Director; Vice President	○	○	○		○		○	
Masato Chikira	Director; Executive Officer	○			○	○			
Norihisa Takebe	Director; Executive Officer	○				○	○		○
Yasushi Narabe	Director; Operating Officer			○					
Hideaki Osawa	Director; Operating Officer					○			
Toshiyuki Kondo	Outside Director	○	○			○			
Yukiko Yoritaka	Outside Director						○	○	○
Tatsuharu Arai	Outside Director	○		○					

Corporate Auditors:

Name	Positions in the Company	Areas which the Company specifically expect candidates for Corporate Auditors to cover							
		Management Experience	Medical Experience	Inspection/Engineering	Information Technology	Strategy Planning	Finance/Accounting	Personnel/Labor	Risk/Legal Affairs
Kenichi Morishita	Corporate Auditor						○	○	○
Nobushige Tokuono	Outside Corporate Auditor						○	○	
Masato Denawa	Outside Corporate Auditor							○	○

The above list does not present all of the knowledge and experience possessed by the candidates.